Biogen executive awarded 8,025 restricted stock units

Keeney Adam reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 02/17/2026 - 08:12 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Keeney Adam reported acquisition or exercise transactions in this Form 4 filing.

Biogen Inc. executive Adam Keeney, Head of Corporate Development, reported an award of 8,025 restricted stock units. These RSUs were granted at no purchase price and represent the right to receive Biogen common shares upon vesting. The units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.

Insider Trade Summary

Grant/Award: 8,025 shares

Grant/Award 1 txn

Insider Keeney Adam

Role Head of Corporate Development

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	8,025	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 8,025 contracts (Direct)

Holdings Before and After: Restricted Stock Unit, 0 to 8,025 contracts (Direct)

Footnotes (1)

F1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Biogen (BIIB) report for Adam Keeney?

Biogen reported that Adam Keeney received a grant of 8,025 restricted stock units. These RSUs were awarded at no purchase price and will convert into Biogen common shares only as they vest over three equal annual installments starting one year after February 13, 2026.

Who is Adam Keeney in relation to Biogen (BIIB) and this Form 4?

Adam Keeney is Biogen’s Head of Corporate Development and the reporting person on this Form 4. The filing shows he was granted 8,025 restricted stock units, which vest in three equal yearly tranches beginning on the first anniversary of the February 13, 2026 grant date.

How many restricted stock units did Adam Keeney receive from Biogen (BIIB)?

Adam Keeney received 8,025 restricted stock units from Biogen. According to the filing, all 8,025 units were acquired in a single award and will vest in three equal annual installments, giving him rights to Biogen common shares as each installment vests over time.

What are the vesting terms of Adam Keeney’s Biogen (BIIB) restricted stock units?

The 8,025 restricted stock units vest in three equal yearly installments. Vesting begins on the first anniversary of the February 13, 2026 grant date, meaning one-third of the RSUs will vest each year over three years, subject to the grant’s standard conditions.

Did Adam Keeney buy or sell Biogen (BIIB) shares in this Form 4 filing?

The Form 4 reports an acquisition of restricted stock units as a grant or award, not an open-market trade. Adam Keeney received 8,025 RSUs at no purchase price, which will convert into Biogen common shares only if and when the units vest over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keeney Adam

(Last)

(First)

(Middle)

BIOGEN INC.

225 BINNEY STREET

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Head of Corporate Development

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0	02/13/2026		A		8,025		⁽¹⁾	02/13/2029	Common Stock	8,025	$0	8,025	D

Explanation of Responses:

1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

	/s/ Wendell Taylor, attorney-in-fact for Mr. Keeney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR